Jie Liu

5.3k total citations
204 papers, 4.0k citations indexed

About

Jie Liu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Jie Liu has authored 204 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Molecular Biology, 44 papers in Cancer Research and 27 papers in Oncology. Recurrent topics in Jie Liu's work include Advanced biosensing and bioanalysis techniques (39 papers), Cancer-related molecular mechanisms research (31 papers) and MicroRNA in disease regulation (15 papers). Jie Liu is often cited by papers focused on Advanced biosensing and bioanalysis techniques (39 papers), Cancer-related molecular mechanisms research (31 papers) and MicroRNA in disease regulation (15 papers). Jie Liu collaborates with scholars based in China, United States and South Korea. Jie Liu's co-authors include Lingwen Zeng, Zhiyuan Fang, Junhua Chen, Da‐Chuan Yin, Chen‐Yan Zhang, Peijun Liu, Yanmei Qi, Shaohua Li, Pingping Li and Michael P. Waalkes and has published in prestigious journals such as Nucleic Acids Research, The Journal of Chemical Physics and SHILAP Revista de lepidopterología.

In The Last Decade

Jie Liu

186 papers receiving 4.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jie Liu China 36 2.5k 981 638 494 388 204 4.0k
Michal Masařík Czechia 41 2.5k 1.0× 783 0.8× 742 1.2× 521 1.1× 836 2.2× 175 6.1k
Yue Zhao China 38 2.8k 1.1× 1.0k 1.0× 619 1.0× 354 0.7× 419 1.1× 154 4.5k
Cristina M. Furdui United States 38 2.8k 1.1× 482 0.5× 381 0.6× 458 0.9× 371 1.0× 155 4.9k
Hang Zhang China 40 2.9k 1.2× 856 0.9× 651 1.0× 464 0.9× 1.2k 3.0× 228 5.9k
Ruifang Li China 35 2.8k 1.1× 441 0.4× 357 0.6× 489 1.0× 485 1.3× 206 4.9k
Yue Gao China 34 1.9k 0.8× 560 0.6× 831 1.3× 430 0.9× 401 1.0× 184 3.8k
Xin Luan China 36 2.8k 1.1× 849 0.9× 857 1.3× 329 0.7× 619 1.6× 165 5.1k
Ke Jin China 40 2.9k 1.1× 869 0.9× 584 0.9× 374 0.8× 544 1.4× 152 7.8k
Yun Chen China 33 2.3k 0.9× 672 0.7× 519 0.8× 216 0.4× 692 1.8× 164 3.9k
Taotao Liu China 28 1.8k 0.7× 773 0.8× 307 0.5× 220 0.4× 332 0.9× 86 2.9k

Countries citing papers authored by Jie Liu

Since Specialization
Citations

This map shows the geographic impact of Jie Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jie Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jie Liu more than expected).

Fields of papers citing papers by Jie Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jie Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jie Liu. The network helps show where Jie Liu may publish in the future.

Co-authorship network of co-authors of Jie Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Jie Liu. A scholar is included among the top collaborators of Jie Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jie Liu. Jie Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Yuen, Ho Yin, et al.. (2024). Metronidazole-modified Au@BSA nanocomposites for dual sensitization of radiotherapy in solid tumors. Journal of Materials Chemistry B. 12(38). 9686–9694. 1 indexed citations
4.
Yang, Chao, Jie Liu, Wensheng Zhang, et al.. (2024). Leveraging Senescent Cancer Cell Membrane to Potentiate Cancer Immunotherapy Through Biomimetic Nanovaccine. Advanced Science. 11(30). e2400630–e2400630. 24 indexed citations
5.
Wang, Zheng, Hui Fang, Kai Xiao, et al.. (2024). Reprogramming cellular senescence in the tumor microenvironment augments cancer immunotherapy through multifunctional nanocrystals. Science Advances. 10(44). eadp7022–eadp7022. 10 indexed citations
6.
Liu, Jie, Tongyao Yu, Ge Zhang, et al.. (2023). Recent progress of mechanosensitive mechanism on breast cancer. Progress in Biophysics and Molecular Biology. 185. 1–16. 4 indexed citations
7.
Zhang, Xinpeng, Xinyu Li, Danfeng Wang, et al.. (2023). Spectroscopic, calorimetric and cytotoxicity studies on the combined binding of daunorubicin and acridine orange to a DNA tetrahedron. Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy. 295. 122583–122583. 5 indexed citations
8.
Liao, Chunyan, Xiang Wang, Dequan Wang, et al.. (2022). Dietary Antioxidant-Constructed Nanodrugs Can High-Efficiently Kill Cancer Cells while Protecting Noncancer Cells. ACS Applied Materials & Interfaces. 14(44). 49508–49520. 8 indexed citations
9.
Wang, Bo, Can Zhou, Su Chen, et al.. (2021). TAZ maintains telomere length in TNBC cells by mediating Rad51C expression. Breast Cancer Research. 23(1). 89–89. 8 indexed citations
10.
Liu, Jie, Juan Li, He Chen, et al.. (2020). Metformin suppresses proliferation and invasion of drug‐resistant breast cancer cells by activation of the Hippo pathway. Journal of Cellular and Molecular Medicine. 24(10). 5786–5796. 40 indexed citations
11.
Li, Juan, Jie Liu, Pingping Li, et al.. (2019). Downregulation of WW domain-containing oxidoreductase leads to tamoxifen-resistance by the inactivation of Hippo signaling. Experimental Biology and Medicine. 244(12). 972–982. 2 indexed citations
12.
Chen, Ying, Yongchao Yao, Chunyan Liao, et al.. (2019). Cascade-Reaction-Based Nanodrug for Combined Chemo/Starvation/Chemodynamic Therapy against Multidrug-Resistant Tumors. ACS Applied Materials & Interfaces. 11(49). 46112–46123. 63 indexed citations
13.
Li, Pingping, Jie Liu, Juan Li, & Peijun Liu. (2019). DNA methylation of CRB3 is a prognostic biomarker in clear cell renal cell carcinoma. Molecular Biology Reports. 46(4). 4377–4383. 5 indexed citations
14.
Liu, Jie, Pingping Li, Ruiqi Wang, et al.. (2019). High expression of DLG3 is associated with decreased survival from breast cancer. Clinical and Experimental Pharmacology and Physiology. 46(10). 937–943. 14 indexed citations
15.
Li, Pingping, Can Zhou, Yu Yan, et al.. (2019). Crumbs protein homolog 3 (CRB3) expression is associated with oestrogen and progesterone receptor positivity in breast cancer. Clinical and Experimental Pharmacology and Physiology. 46(9). 837–844. 2 indexed citations
16.
Liu, Jie, Juan Li, Pingping Li, et al.. (2018). DLG5 suppresses breast cancer stem cell‐like characteristics to restore tamoxifen sensitivity by inhibiting TAZ expression. Journal of Cellular and Molecular Medicine. 23(1). 512–521. 30 indexed citations
17.
Liao, Chunyan, Xin Dai, Ying Chen, et al.. (2018). Biogenic (R)‐(+)‐Lipoic Acid Only Constructed Cross‐Linked Vesicles with Synergistic Anticancer Potency. Advanced Functional Materials. 29(3). 57 indexed citations
18.
Li, Pingping, Cheng Feng, He Chen, et al.. (2018). ElevatedCRB3 expression suppresses breast cancer stemness by inhibiting β‐catenin signalling to restore tamoxifen sensitivity. Journal of Cellular and Molecular Medicine. 22(7). 3423–3433. 18 indexed citations
19.
Jia, Xiaowei, Qingjun Liu, Yanshu Zhang, et al.. (2014). Myelin protein zero and its antibody in serum as biomarkers of n -hexane-induced peripheral neuropathy and neurotoxicity effects. Chinese Medical Journal. 127(8). 1536–1540. 6 indexed citations
20.
Liu, Jie. (2005). MRSA Infection: An Epidemiology Survey. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michal Masařík Breakdown of academic impact, for papers by Yue Zhao Breakdown of academic impact, for papers by Cristina M. Furdui Breakdown of academic impact, for papers by Hang Zhang Breakdown of academic impact, for papers by Ruifang Li Breakdown of academic impact, for papers by Yue Gao Breakdown of academic impact, for papers by Xin Luan Breakdown of academic impact, for papers by Ke Jin Breakdown of academic impact, for papers by Yun Chen Breakdown of academic impact, for papers by Taotao Liu
Rankless by CCL
2026